Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
78
-
Total 13F shares, excl. options
-
30.2M
-
Shares change
-
+1.62M
-
Total reported value, excl. options
-
$79.9M
-
Value change
-
+$6.83M
-
Put/Call ratio
-
1.45
-
Number of buys
-
47
-
Number of sells
-
-31
-
Price
-
$2.65
Significant Holders of Jade Biosciences, Inc. - COM (AVTE) as of Q4 2024
102 filings reported holding AVTE - Jade Biosciences, Inc. - COM as of Q4 2024.
Jade Biosciences, Inc. - COM (AVTE) has 78 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.2M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (9.19M shares), Sofinnova Investments, Inc. (3.76M shares), TCG Crossover Management, LLC (2.24M shares), Atlas Venture Life Science Advisors, LLC (1.8M shares), BRAIDWELL LP (1.44M shares), Logos Global Management LP (1.4M shares), VANGUARD GROUP INC (1M shares), BlackRock, Inc. (975K shares), ADAR1 Capital Management, LLC (928K shares), and Allostery Investments LP (851K shares).
This table shows the top 78 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.